A Placebo-Controlled, Randomized, Double-Blind Study of Adjunctive Bupropion Sustained Release in the Treatment of SSRI-Induced Sexual Dysfunction
J Clin Psychiatry 2005;66(7):844-848
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Sexual side effects are among the
common reasons patients discontinue selective serotonin reuptake
inhibitors (SSRIs). While many antidotes have been proposed, few
have been subjected to double-blind trials. Some evidence has
suggested that bupropion may be an effective antidote for
SSRI-induced sexual dysfunction. In this double-blind trial, the
efficacy of a standard dose of bupropion sustained release (SR)
is evaluated in the treatment of SSRI-induced sexual dysfunction.
Method: Patients with a history of SSRI-induced
sexual side effects were randomly assigned to adjunctive
treatment with either bupropion SR 150 mg daily or placebo for 6
weeks. Assessments of sexual function and interest included the
Arizona Sexual Experiences Scale (ASEX), Brief Index of Sexual
Functioning, and a 10-point visual analogue scale. Efficacy was
defined as a 50% improvement on the ASEX at the end of 6 weeks.
Data were collected from January 1999 to March 2001.
Results: Forty-one patients entered the study
and completed the 6-week trial. No significant differences were
seen between placebo and bupropion SR on the ASEX or on any
measure of sexual functioning at the end of the trial.
Conclusion: A fixed dose of 150 mg/day of
bupropion SR taken in the morning does not appear to be effective
in the treatment of SSRI-induced sexual dysfunction. Additional
trials will be required to define what role, if any, bupropion
might have in the treatment of SSRI-induced sexual side effects.